Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline Review, H2 2016, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline landscape.
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 8 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections.
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Destiny Pharma Ltd
Galapagos NV
MGB Biopharma Ltd
Syntiron LLC
Techulon Inc
Valevia UK Ltd
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview 7
Therapeutics Development 8
Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview 8
Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 9
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Development by Companies 10
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 11
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Development by Companies 14
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Products under Investigation by Universities/Institutes 15
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development 16
Destiny Pharma Ltd 16
Galapagos NV 17
MGB Biopharma Ltd 18
Syntiron LLC 19
Techulon Inc 20
Valevia UK Ltd 21
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
acALY-18 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
exeporfinium chloride - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GLPG-1492 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MGBBP-3 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
MH-003 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Siderocillin - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Staphylococcus aureus vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
VAL-301 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects 43
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products 44
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones 45
Featured News & Press Releases 45
Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 4
List of Tables
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2016 8
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Ltd, H2 2016 16
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Galapagos NV, H2 2016 17
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, H2 2016 18
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC, H2 2016 19
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc, H2 2016 20
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H2 2016 43
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H2 2016 44
List of Figures
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2016 8
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Targets, H2 2016 23
Number of Products by Stage and Targets, H2 2016 23
Number of Products by Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
